NEW YORK (GenomeWeb News) – Rubicon Genomics will amplify and standardize DNA samples from cancer patients for the Cancer Genome Atlas, the Ann Arbor, Mich.-based company said today.
Under an agreement with SAIC-Frederick, Rubicon will use its GenomePlex whole-genome amplification technology on more than 3,000 blood and tissue samples. The DNA libraries will be deposited in the International Genomics Consortium’s Biospecimen Research Core, where they will be shared among international researchers taking part in the TCGA project.
Rubicon’s VP of commercial development, John Langmore, said in a statement that IGC collaborators showed “that pre-amplification of patient DNA can increase the sensitivity, reproducibility and robustness of analysis of patient samples using major analytical instruments."
Financial terms of the agreement were not released.